Can multimodal AI guide liver-cancer care yet? A 28-model review says not yet
Models combining scans, clinical records and molecular data often reported promising predictions, but a new peer-reviewed review found no prospective clinical-impact study or randomised trial—and basic reporting gaps remain common.
The short version
- What happened
- The peer-reviewed narrative review appraised 28 multimodal AI prediction models spanning diagnosis, grading or microvascular invasion, treatment response, and prognosis or recurrence.
- Who it affects
- People with liver cancer need evidence that a prediction changes care for the better, not only that it fits retrospective records. Premature use could misclassify risk or steer treatment using models that have not been tested in the population receiving care.
- What remains unproven
- This is a peer-reviewed narrative review rather than a preregistered systematic review or meta-analysis; it searched four databases and literature published through 2025.
Keep in mind
This is a peer-reviewed narrative review rather than a preregistered systematic review or meta-analysis; it searched four databases and literature published through 2025.
The 28-model audit mixes different tasks, data types and endpoints, so reported performance cannot be pooled or compared as if all models answered the same question.
The review team was based in one Chinese university system, received Hunan provincial public funding and declared no competing interests. The authors disclosed ChatGPT-4o use for writing and language polishing, not for the literature collation or analysis.
No included study demonstrated prospective clinical benefit, and evidence was heavily weighted toward East Asian viral-hepatitis populations.
Source analysis · 1 linked source. Primary analysed source date: 22 October 2026.
Keep following the evidence
Join The Impact Brief founding list for selected AI reports, their effect on people and the evidence limits. Read a sample first.
Read the full report · 4 min The evidence, methods, implications and limitations
The review asks a clinical question performance scores cannot answer
Multimodal AI tries to combine two or more sources—such as CT or MRI scans, digital pathology, genomic measurements and ordinary clinical records—to characterise a liver tumour more completely than one source alone. A peer-reviewed narrative review published on 22 October examined how far that promise has travelled toward care for hepatocellular carcinoma, the most common primary liver cancer.
The authors searched PubMed, Web of Science, the Cochrane Library and China National Knowledge Infrastructure for work published through 2025. They then appraised 28 prediction models across four tasks: diagnosis, grading or microvascular invasion, treatment-response assessment, and prognosis or recurrence. This was not a systematic review or meta-analysis, so the set should be read as a structured evidence map rather than a guaranteed census or pooled estimate of performance.[1]
The validation ledger is stronger than a prototype—but short of clinical evidence
Twenty-seven models—96.4%—came from retrospective studies; the remaining one was an animal experiment. Nineteen used multicentre data and 19 reported external validation, while 21 used an independent test set. Those are useful safeguards against a model merely memorising one hospital's data. Yet none of the 28 reached the review's highest evidence level: a prospective study or clinical-impact test. No randomised trial showed that using a model improved a decision, survival, quality of life or another patient outcome.
Important reporting checks were uneven. Twenty-seven studies gave confidence intervals, but only 10 reported calibration—whether predicted risks match observed risks. Ten reported decision-curve analysis and predefined endpoints. Just three addressed class imbalance, while seven described how missing data were handled. None explicitly followed any of five AI-specific reporting or bias guidelines checked by the reviewers. Strong headline accuracy or area-under-the-curve results cannot repair those gaps.[1]
The distinction that matters
What the 28-model evidence map actually shows
The review separates promising development signals from the evidence needed to change care.
Inputs
Combine imaging, pathology, molecular and clinical data
Build a richer tumour representation
Validation
Use multicentre data, an external cohort and an independent test set
Reduce—but do not remove—overfitting risk
Clinical test
Prospectively compare AI-assisted care with current practice
No included model reached this level
For patients, the useful message is restraint rather than rejection
Combining routinely collected information could eventually help clinicians detect atypical tumours, estimate microvascular invasion before surgery, anticipate treatment response or tailor follow-up. But the review does not justify choosing therapy from a multimodal score today. Models trained mainly on East Asian viral-hepatitis cohorts may also travel poorly to populations where metabolic liver disease is more common; the authors found no multimodal study specifically focused on Western metabolic-disease-related liver cancer.
The assessment would change with preregistered prospective, multinational studies that compare AI-assisted decisions with standard care, report calibration and missing-data handling, and measure patient outcomes as well as model performance. Until then, these systems are research tools—not replacements for imaging, pathology, liver-function assessment or multidisciplinary clinical judgement.[1]
Watch the background, then check the evidence
Illustrative photo · not a video frame
The Royal Society · 44 min 28 sec · Background explainer
Is this the AI future we want? | The Royal Society
YouTube loads only when you choose; playback starts when you press play.
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Published 2026-07-01. Source checked 14 October 2026. Check captions on the publisher’s video page.
Check the healthcare evidencePhoto: Daniel Sone / National Cancer Institute / Unsplash · Licence
Continue the story
Read next
Continue exploring medical imaging: compare the finding and its evidence limits.
Can AI support breast-ultrasound decisions across countries?
A peer-reviewed South Korean-led study validated an interpretable retrieval-augmented system across 8,311 images from 11 cohorts in seven countries and tested assistance with four readers. The retrospective evidence is encouraging, but it is not a prospective screening trial or proof of better patient outcomes.
Read the next reportExplore the full source and evidence record
What this means for people
- People with liver cancer need evidence that a prediction changes care for the better, not only that it fits retrospective records. Premature use could misclassify risk or steer treatment using models that have not been tested in the population receiving care.
Global context
Liver-cancer causes and care pathways vary substantially. Hepatitis B remains a major driver in East Asia, while metabolic liver disease is increasingly important elsewhere. A model's usefulness therefore depends on validation across causes, ethnic groups, hospitals, scanners and treatment systems.
What the evidence does not yet show
- This is a peer-reviewed narrative review rather than a preregistered systematic review or meta-analysis; it searched four databases and literature published through 2025.
- The 28-model audit mixes different tasks, data types and endpoints, so reported performance cannot be pooled or compared as if all models answered the same question.
- The review team was based in one Chinese university system, received Hunan provincial public funding and declared no competing interests. The authors disclosed ChatGPT-4o use for writing and language polishing, not for the literature collation or analysis.
- No included study demonstrated prospective clinical benefit, and evidence was heavily weighted toward East Asian viral-hepatitis populations.
What to watch next
- Preregistered prospective and randomised impact studies
- Validation in Western metabolic-disease-related liver cancer cohorts
- Calibration, missing-data and class-imbalance reporting
- Proof that an AI-supported decision improves outcomes beyond established clinical staging
Living evidence record
Impact record IAI-157SIZT
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
22 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what Journal of Hepatocellular Carcinoma published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 22 October 2026
Research question, topics and regions
Whether multimodal AI models for hepatocellular carcinoma have been validated strongly enough to improve real clinical decisions or patient outcomes
Topics: Liver cancer · Clinical AI · Medical imaging · Precision oncology · Evidence standards
Regions: China · East Asia · Global
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.